(R)-Methanandamide, but not anandamide, substitutes for Δ9-THC in a drug-discrimination procedure

Experimental and Clinical Psychopharmacology

Volumn 5, Issue 3, 1997, Pages 195-202

  Burkey, Robert T ^a   Nation, Jack R ^b  

^a EMORY AND HENRY COLLEGE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABINOID RECEPTOR; DRONABINOL; METHANANDAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG EFFECT; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; RAT; REINFORCEMENT; RESEARCH;

ANIMALS; ARACHIDONIC ACIDS; CANNABINOIDS; CYCLOHEXANOLS; DISCRIMINATION (PSYCHOLOGY); DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; GENERALIZATION, STIMULUS; HALLUCINOGENS; MALE; POLYUNSATURATED ALKAMIDES; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDROCANNABINOL;

EID: 0030744309     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/1064-1297.5.3.195     Document Type: Article

References (32)

1. Abadji, V., Lin, S., Taha, G., Griffin, G., Stevenson, L. A., Pertwee, R. G., & Makriyannis, A. (1994). (R)-Methanandamide: A chiral novel anandamide possessing higher potency and metabolic stability. Journal of Medical Chemistry, 37, 1889-1893.
2. 9-tetrahydrocannabinol: Mechanistic studies. Journal of Clinical Pharmacology, 21, 227-234.
3. Childers, S. R., Sexton, T., & Roy, M. B. (1994). Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochemical Pharmacology, 47, 711-715.
4. Colpaert, F. C. (1991). The discriminative response: An elementary particle of behavior. Behavioural Pharmacology, 2, 283-286.
5. Crawley, J. N., Corwin, R. L., Robinson, J. K., Felder, C. C., Devane, W. A., & Axelrod, J. (1993). Anandamide, and endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacology Biochemistry & Behavior, 46, 967-972.
6. Deutsh, D. G., & Chin, S. A. (1993). Enzymatic synthesis and degradation on anandamide, a cannabinoid receptor agonist. Biochemical Pharmacology, 46, 791-796.
7. Devane, W. A., & Axelrod, J. (1994). Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proceedings of the National Academy of Sciences, USA, 14, 6698-6701.
8. Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988). Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology, 34, 605-613.
9. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992). Isolation and structure of a brain constituent which binds to the cannabinoid receptor. Science, 258, 1946-1949.
10. Dewey, W. L. (1986). Cannabinoid pharmacology. Pharmacological Reviews, 38, 151-178.
11. Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwarts, J. C., & Piomelli, D. (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 372, 686-691.
12. Fride, E., & Mechoulam, M. (1993). Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. European Journal of Pharmacology, 231, 313-314.
13. Gaoni, Y., & Mechoulam, R. (1964). Isolation, structure and partial synthesis of an active constituent of hashish. Journal of the American Chemistry Society, 86, 1646-1647.
14. Gerard, C., Mollereau, C., Vassart, G., & Parmentier, M. (1990). Nucleotide sequence of a human cannabinoid receptor cRNA. Nucleic Acids Research, 18, 7142.
15. Gerard, C. M., Mollereau, C., Vassart, G., & Parmentier, M. (1991). Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochemical Journal, 279, 129-134.
16. Glennon, R. A., Rosecrans, J. A., & Young, R. (1982). The use of the drug-discrimination paradigm for studying hallucinogenic agents: A review. In F. C. Colpaert & J. L. Slangen (Eds.), Drug discrimination: Applications in CNS pharmacology (pp. 69-96). Amsterdam: Elsevier Biomedical Press.
17. 9-THC and CP 55,940 in rats and rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics, 262, 479-486.
18. Howlett, A. C., Johnson, M. R., Melvin, L. S., & Milne, G. M. (1988). Nonclassical cannabinoid analgesics inhibition adenylate cyclase: Development of a cannabinoid receptor model. Molecular Pharmacology, 33, 297-302.
19. i in the inhibition of adenylate cyclase by cannabimimetic drugs. Molecular Pharmacology, 29, 307-313.
20. Kruszka, K. K., & Gross, R. W. (1994). The ATP- and CoA-independent synthesis of arachidonoylethanolamide. The Journal of Biochemical Chemistry, 269, 14345-14348.
21. Mackie, K., Devane, W. A., & Mille, B. (1993). Anadamide, an endogenous cannabinoid, inhibits calcium currents as partial agonist in N18 neuroblastoma cells. Molecular Pharmacology, 44, 498-503.
22. Matsuda, L. A., Lolait, J. S., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Letters to Nature, 346, 561-564.
23. Mechoulam, R., Devane, W. A., & Glasser, R. (1992). Cannabinoid geometry and biological activity. In L. Murphy & A. Bartke (Eds.), Marijuana/cannabinoids: Neurobiology and neurophysiology (pp. 1-33). Boca Raton, FL: CRC Press.
24. Pertwee, R. G., Stevenson, L. A., & Griffin, G. (1993). Crosstolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP-55,940, WIN 55,212-2 an anandamide. British Journal of Pharmacology, 110, 1483-1490.
25. 1 receptor ligand. Life Sciences, 58, 1249-1257.
26. Smith, P. B., Compton, D. R., Welch, S. P., Razdan, R. K., Mechoulam, R., & Martin, B. R. (1994). The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. The Journal of Pharmacology and Experimental Therapeutics, 270, 219-227.
27. Swedberg, M. D. B., & Jarbe, T. U. C. (1982). Morphine cue saliency: Limits of discriminability and third state perception by pigeons. In F. C. Colpaert & J. L. Slangen (Eds.), Drug discrimination: Applications in CNS pharmacology (pp. 147-164). Amsterdam: Elsevier Biomedical Press.
28. Vogel, Z., Barg, J., Levy, R., Saya, D., Heldman, E., & Mechoulam, R. (1993). Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. Journal of Neurochemistry, 61, 352-355.
29. Wiley, J. L., Balster, R. L., & Martin, B. R. (1995). Discriminative stimulus effects of anandamide in rats. European Journal of Pharmacology, 276, 49-54.
30. Wiley, J. L., Lowe, J. A., Balster, R. L., & Martin, B. R. (1995). Antagonism of the discriminative stimulus effects of delta-9-tetrahydrocannabinol in rats and rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics, 275, 1-6.
31. Wong, K. C., & Lien-Teh, W. (1936). The history of Chinese medicine (p. 4). Shanghai, China: National Quarantine Service.
32. Young, A. M., Kapitsopoulos, G., & Makhay, M. M. (1991). Tolerance to morphine-like stimulus effects of mu opioid agonists. The Journal of Pharmacology and Experimental Therapeutics, 257, 795-805.